Skip to content

The Impact of Germanium-Embedded Knee Brace on Patient Recovery After ACL Reconstruction

The Impact of Germanium-Embedded Knee Brace on Patient Recovery After ACL Reconstruction: a Blinded and Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05068297
Enrollment
100
Registered
2021-10-05
Start date
2021-11-30
Completion date
2022-10-01
Last updated
2021-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anterior Cruciate Ligament Injuries

Brief summary

Anti-inflammatory brace technology has demonstrated superior clinical outcomes in the management of knee osteoarthritis and accelerate recovery time for Major League Soccer players. Authors have postulated that embedding germanium into cotton garments increases circulation and augments the inflammatory process through a transdermal micro-electromagnetic field. In addition to immunomodulatory effects, knee braces immobilize and stabilize the joint through tactile feedback from the skin. Thus, a germanium-embedded knee brace may provide inflammatory control to augment pain and edema while concomitantly enhancing proprioception. ACL Reconstruction rehabilitation goals during the acute post-operative phase include diminishment of pain and edema as well as restoration of knee range-of-motion. The presented study intends to assess the impact of a germanium-embedded knee brace on patient recovery after ACL reconstruction. Single-center blinded randomized controlled clinical trial to study effectiveness of germanium-infused knee brace on rehabilitation in patient population undergoing ACL reconstruction. Patients will be randomized into germanium-infused knee brace group and compared to a replica knee brace group. Inclusion criteria will include skeletally mature individuals undergoing primary ACL reconstruction. Exclusion criteria will include autoimmune disorders and history of surgery on ipsilateral joint. The presented protocol intends to assess the impact of a germanium-embedded knee brace on patient recovery after ACL reconstruction. The primary outcome measure was chosen for its implications for the design and conduct of the study,1 including well-validated outcome instrument for comparison, facilitation of a priori power analysis, randomization, and blinding. Secondary outcomes were chosen for their pertinence to surgeon decision-making during patient rehabilitation.

Interventions

OTHERIncrediwear Germanium-Embedded Knee Brace following ACL reconstruction

Germanium-Embedded Knee Brace will be applied to the effected limb following ACL reconstruction

Replica Knee brace will be applied to the effected limb following ACL reconstruction

Sponsors

Total Sports Medicine & Orthopedics
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* 18-100 years old * Male or female * Compliant patient * BMI less than 35 * Undergoing ACL reconstruction within 30 days

Exclusion criteria

* Rheumatoid Arthritis * Poorly controlled diabetes (HgA1c \> 7.5) * Previous blood clots * BMI greater than 35 * Varicosities on operative leg

Design outcomes

Primary

MeasureTime frameDescription
Short Form 36 (SF-36)4 weeksA well-validated patient reported outcome and the most commonly used outcome instrument in orthopaedics.

Secondary

MeasureTime frameDescription
Knee Range of Motion6 weeksIn degrees, measured by a senior surgeon using a Goniometer, at standard post-operative visits
Pain Estimation6 weeksVisual Analog Scale
Leg Circumference6 weeksIn centimeters, measure by senior surgeon during physical exam using a tape measure at standard post-operative visits

Contacts

Primary ContactShanthan C Challa, MD
shanthancchalla@gmail.com7024998579
Backup ContactRoddy McGee

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026